24LBA Safety data from the phase 1b part of the MASTERKEY-265 study combining talimogene laherparepvec (T-VEC) and pembrolizumab for unresectable stage IIIB-IV melanoma Conference Paper uri icon

authors

  • Long, GV
  • Dummer, R
  • Ribas, A
  • Puzanov, I
  • Michielin, O
  • Vanderwalde, A
  • Andtbacka, RHI
  • Cebon, J
  • Fernandez, E
  • Malvehy, J
  • Olszanski, AJ
  • Gajewski, TF
  • Kirkwood, JM
  • Gause, C
  • Chen, L
  • Kaufman, DR
  • Chou, J
  • Hodi, FS

publication date

  • September 2015